EPM
KZR

Equitec Proprietary Markets’s Kezar Life Sciences KZR Stock Holding History

Equitec Proprietary Markets’s Portfolio KZR Stock Details KZR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$145K Buy
+19,500
New +$127K 0.08% 44

Other funds holding KZR

BCM
BML Capital Management Zionsville, Indiana $156M AUM 129.82% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
RC
Rangeley Capital New Canaan, Connecticut $103M AUM 77.32% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $1.94B AUM 374.45% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PLC
Peapod Lane Capital Bedford Hills, New York $122M AUM 67.29% 1-Year Est. Return

Equitec Proprietary Markets's KZR Position: Q1 2026 in Review

Equitec Proprietary Markets opened a new position in Kezar Life Sciences (KZR) in Q1 2026: 19,500 shares worth $145K. The stake represents 0.08% of the portfolio and ranks #44 among its holdings.

43 funds tracked by Wall St. Rank hold KZR as of Q1 2026.

  • Equitec Proprietary Markets held 19,500 shares of Kezar Life Sciences worth $145K as of Q1 2026.
  • Kezar Life Sciences was a new Equitec Proprietary Markets position in Q1 2026.
  • Kezar Life Sciences made up 0.08% of Equitec Proprietary Markets's portfolio in Q1 2026, its #44 holding.
  • 43 funds tracked by Wall St. Rank held Kezar Life Sciences as of Q1 2026.

Based on Equitec Proprietary Markets's 13F filing for Q1 2026, filed 11 May 2026.